AHR ChIP-seq in primary human hepatocytes treated with TCDD. AHR ChIP-seq in primary human hepatocytes treated with TCDD

ChIP-seq was done on cryopreserved primary human hepatocyte with vehicle control - 0.1% dimethylsulfide (DMSO), or 1nM 2,3,7,8 tetrachlorodibezno-p-dioxin (TCDD) agonist treatment to identify AHR binding regions throughout the genome. We identified 1,984 binding peaks when comparing TCDD vs. vehicle control Overall design: Primary human hepatocytes were treated with vehicle control (DMOS) or 1 nM TCDD for 24 hours before cells were collected for ChIP-seq. Sequencing was carried out on Illumina HiSeq 2000